Torkamani 2014.

Study characteristics
Methods	Design: Parallel group randomised study. No. of participant centres: Three European sites: the National Hospital for Neurology and Neurosurgery, London, UK; Badalona Serveis Assistencials, Badalona, Spain; and the Psychiatric Hospital of Attica, Athens, Greece. Study dates: Not reported.
Participants	Inclusion criteria: None stated for caregivers. Care recipients should be hospital outpatients with a diagnosis of dementia; living at home with a full time carer, presenting a Barthel Index score of at least 35 (indicating some degree of independence), and a MMSE of at least 9 and no more than 21 (indicating moderate to mild cognitive impairment). Exclusion criteria: None specified. No. of participants randomised to interventions: ‐ Computerised information platform (n = 30). ‐ Control group without intervention (n = 30). Baseline characteristics: Caregivers: Mean age for participants was 60.7 years (SD = 13.9). No other information is available. Care recipients: Mean age for patients was 78.03 years (SD = 6.91), with a mean disease duration of 3.2 years (SD = 2.18), and a mean MMSE score of 19.32 (SD = 5.0).
Interventions	Experimental: ALADDIN, a computerised information platform to offer support and information to the carer, and to manage distant monitoring with caregivers and clinicians. Control: Assessment at 3 time points without any further contact or intervention. Lenght of intervention: 6 months.
Outcomes	Primary outcomes: ‐ Caregiver burden, assessed by the Zarit Burden Interview (ZBI), (score range 0 to 88; higher scores denote greater burden). ‐ Caregiver depression, assessed by the Beck Depression Inventory (BDI; score range 0 to 63, higher scores denote more depressive symptoms) and the Zung Depression Self Rating Scale (ZDSR, score range 20 to 80, higher scores represent more severe depression). ‐ Caregiver quality of life, assessed by the EuroQoL (EQ5D, summary index value of 0‐1, lower scores represent poorer QoL), and the Quality of Life Scale (QOLS, score range 16 to 112, higher scores indicate better QoL). Secondary outcomes: Not stated. Outcomes assessment: At 3 (intermediate assessment) and 6 months (final assessment).
Notes	Clinical trial registration code: Not reported. Funding: Grant from the Ambient Assisted Living, European Commission. Conflicts of interest: None declared.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: Study reported as randomised but there is no information on the randomization procedure.
Allocation concealment (selection bias)	Unclear risk	Comment: There is no information on allocation concealment.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Comment: Participants and personnel were not blinded to interventions.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Comment: There is no information on blinding of outcome assessors. Moreover, this is an unmasked study with participants not masked to interventions, subjective participant‐reported outcomes and not comparable intervention components and procedures.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: There is no information to figure out the flowchart of the study.
Selective reporting (reporting bias)	Unclear risk	Comment: There is no trial registry and/or available protocol.
Other bias	Low risk	Comment: None detected.